Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer. (7th August 2019)

• Record Type: Journal Article
• Authors: Cheng, Songtao; Wang, Gang; Wang, Yejinpeng; Cai, Liwei; Qian, Kaiyu; Ju, Lingao; Liu, Xuefeng; Xiao, Yu; Wang, Xinghuan
• Is Part Of: Clinical science. Volume 133:Number 15(2019)
• Page Start: 1745
• Page End: 1758
• Publication Date: 2019-08-07
• Subjects: bladder cancer -- cell cycle -- etomoxir -- fatty acid oxidation -- PPARγ; Medicine -- Periodicals; Biochemistry -- Periodicals; 616
• DOI: 10.1042/CS20190587
• Languages: English
• ISSNs: 0143-5221

Abstract

Abstract: Tumor cells rely on aerobic glycolysis as their main energy resource (Warburg effect). Recent research has highlighted the importance of lipid metabolism in tumor progression, and certain cancers even turn to fatty acids as the main fuel. Related studies have identified alterations of fatty acid metabolism in human bladder cancer (BCa). Our microarray analysis showed that fatty acid metabolism was activated in BCa compared with normal bladder. The free fatty acid (FFA) level was also increased in BCa compared with paracancerous tissues. Inhibition of fatty acid oxidation (FAO) with etomoxir caused lipid accumulation, decreased adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide phosphate (NADPH) levels, suppressed BCa cell growth in vitro and in vivo, and reduced motility of BCa cells via affecting epithelial–mesenchymal transition (EMT)-related proteins. Furthermore, etomoxir induced BCa cell cycle arrest at G0 /G1 phase through peroxisome proliferator-activated receptor (PPAR) γ-mediated pathway with alterations in fatty acid metabolism associated gene expression. The cell cycle arrest could be reversed by PPARγ antagonist GW9662. Taken together, our results suggest that inhibition of FAO with etomoxir may provide a novel avenue to investigate new therapeutic approaches to human BCa.